ABSTRACT Background: Obesity is considered a low-grade inflammatory state that improves with weight loss. In addition to acute-phase proteins, other cytokines might contribute to systemic inflammation. Objective: Our objective was to compare serum concentrations of a large panel of inflammation-related factors in obese and normalweight subjects and to determine kinetic changes induced by caloric restriction. Design: The cohort comprised 14 normal-weight women and 51 obese women who were followed over 2 y after Roux-en-Y gastric bypass. Multiplexed proteomics were used to simultaneously assay 27 cytokines and growth factors in serum. Results: Concentrations of interleukin (IL)-9, IL-1-receptor antagonist, IL-10, interferon-c-inducible protein 10, macrophage inflammatory protein 1b, monocyte chemoattractant protein 1, IL-8, RANTES (regulated upon activation, normal T cell expressed and secreted), monokine induced by interferon-c, and vascular endothelial growth factor were found to be elevated in obesity. IL-10 was further elevated in diabetic obese patients, whereas eotaxin was found to be higher only in diabetic subjects. After surgery, many factors showed a biphasic pattern of variation, decreasing sharply at month 3 before rising back to presurgical values at month 6; these changes closely tracked similar kinetic changes in calorie and carbohydrate intake. After 1 y, an overall reduction in cytokines accompanied the reduction in body mass index and an amelioration in metabolic status. Conclusions: Obesity is associated with elevated circulating concentrations of a large panel of cytokines. Coordinated kinetic changes during weight loss suggest an early influence of calorie and carbohydrate intakes, whereas a longer-term reduction in corpulence might prevail in regulating circulating cytokine concentrations. This trial is registered at clincaltrials.gov as NCT00476658.
INTRODUCTION
Increased adipose tissue mass in obese individuals contributes to the development of many comorbidities that can result in serious health consequences. Obesity is now recognized as a state of chronic low-grade inflammation, characterized by an increase in systemic acute phase proteins [C-reactive protein (CRP) and serum amyloid A (SAA)] and obesity-related inflammatory markers such as interleukin (IL)-6 and IL-1 (1) . Part of the systemic inflammation originates from adipose tissue, in which inflammatory cells, mainly macrophages, accumulate and create local inflammation (2) (3) (4) . Adipose-derived inflammatory factors produced by enlarged adipocytes and/or by adipose tissue macrophages are elevated in the serum of obese subjects and are thought to contribute to metabolic and vascular complications, including insulin resistance, atherosclerosis, and liver diseases (5) . Other mechanisms are also implicated in obesity-related systemic inflammation, including the activation of circulating immune cells (6) (7) (8) and inflamed vascular endothelium (9) , which are potentially influenced by nutrient excess, hyperglycemia, dyslipidemia, or oxidative stress.
Weight reduction resulting from nutritional intervention or gastric surgery significantly improves the systemic and adipose tissue inflammatory states associated with obesity (4, (10) (11) (12) . This amelioration relies on a regular and continuous reduction in CRP, SAA, or IL-6 concentrations, correlating with a parallel decrease in body mass index (BMI) (13) . Other recently described molecules, such as chemerin, a chemoattractant protein associated with inflammatory processes, also decrease markedly in the serum after Roux-en-Y Gastric Bypass (RYGB)-induced weight loss (14) . Despite these results however, the large battery of obesity-related cytokines and their variations in relation to weight reduction is far from established. In the current study we tested the possibility that cytokines would show distinct patterns according to their known pro-or antiinflammatory function. Moreover, we sought to test whether changes in circulating cytokine concentrations rely on adipose mass reduction and/or on amelioration of metabolic factors, such as insulin resistance.
RYGB intervention is the most effective method for reducing body weight and improving metabolism in severely obese individuals. The bioclinical outcomes of RYGB include marked changes in quantitative and qualitative food intake, reduced body fat mass, and amelioration of blood glucose, insulin resistance, and lipid variables. Here, we took advantage of the drastic and rapid RYGB-associated weight loss, coupled with caloric restriction and significant variations in macronutrient intake, to explore the kinetics of circulating inflammation-related factors. We used multiplexed proteomics to simultaneously assess a large panel of cytokines, chemokines, and growth factors in the serum at 4 consecutive short-and long-term time points after RYGB. Correlation analyses with bioclinical measures were performed to address the potential regulatory factors contributing to variations in systemic inflammation in human obesity and weight loss.
SUBJECTS AND METHODS

Subjects
For this study, 51 obese women involved in a gastric surgery program were prospectively recruited between 2007 and 2009 in the Department of Nutrition, Center of Reference for Medical and Surgical Care of Obesity (CREMO; Pitié-Salpêtrière Hospital, Paris, France). Patients meeting the criteria for obesity surgery included those having a BMI (kg/m 2 ) 40 or 35 with at least one comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea syndrome). The preoperative evaluation of patients included a detailed medical history and physical, nutritional, metabolic, cardiopulmonary, and psychological assessments. The weight of the subjects included had been stable (variation of less than 6 2 kg) for 3 mo before surgery. Subjects did not show evidence of acute or chronic inflammatory disease, infectious diseases, cancer, and/or known alcohol consumption (.20 g/d) at any time point. Patients displaying surgical complications during the first year after surgery were subsequently excluded. Clinical and biological variables were assessed before RYGB (baseline) and 3, 6, 12, and 24 mo after surgery. Eighteen subjects were classified as having type 2 diabetes, defined as a fasting glucose concentration .7 mmol/L or the use of an antidiabetic drug. These 18 subjects (Ob/D group) were treated with metformin and hypolipemic drugs (either fibrates or statins). Two subjects were additionally treated with insulin. An oral-glucose-tolerance test was performed before RYGB and confirmed that all patients in the nondiabetic obese group had glucose concentrations ,11 mmol/L (200 mg/dL) in the 2 h after a 75-g oral glucose challenge. One year after surgery, 11 of the 18 Ob/D individuals were reclassified as having normoglycemia (glycated hemoglobin ,6.5%), which permitted them to cease antidiabetic treatment. Body fat mass was determined by dual-energy X-ray absorptiometry (DXA; GE Lunar Prodigy Corporation, Madison, WI) in obese and Ob/D subjects. Three obese individuals (n = 2 obese; n = 1 Ob/D), who had preoperative weight exceeding the limit of the analyzer (160 kg) or did not fit entirely within the DXA field-of-view were found in our population. An additional 14 normal-weight, nondiabetic, and healthy female volunteers living in the same area as the obese subjects were recruited as the control group (C group). The study was conducted in accordance with the Helsinski Declaration and was registered in a public trials registry. The Ethics Committee (CPP Ile-de-France 1) approved the clinical investigations for both obese and nonobese individuals. All subjects provided written informed consent.
Dietary and nutritional assessment
The estimated calorie intake (kcal/d) and the amounts of macronutrients (g/d) were recorded by a registered dietitian during the first year after RYGB. Multivitamins and iron supplements were provided to avoid deficiencies, which is a wellknown secondary effect of bariatric surgery (15) . Serum iron, ferritin, the coefficient of saturation of iron in transferrin, vitamins (A, D, E, thiamine, B-12, and B-9), micronutrients (selenium and zinc), and calcium were measured by using routine bioclinical tests. Serum measurements of these aforementioned variables showed that they conformed to the normal range at all time points in all subjects (data not shown).
Metabolic and inflammatory variables
Venous blood samples were collected in the fasting state at each time point for routine measurement of the biochemical variables outlined elsewhere (13) . QUICKI (Quantitative Insulin Sensitivity Check Index) was determined by a mathematical transformation of fasting blood glucose and insulin measurements (16) . Serum samples were stored at 280°C for later assessment of other biological components, including leptin, adiponectin, acute phase response markers measured in routine evaluations in our clinical department [high-sensitivity (hs)-CRP, IL-6], and inflammatoryrelated factors. Serum leptin and adiponectin were determined by using a radioimmunoassay kit from Linco Research (Saint Louis, MO) following the manufacturer's recommendations. The sensitivity was 0.5 ng/mL for leptin and 0.8 lg/mL for adiponectin. Intraassay and interassay CVs were ,4 and ,9% for leptin and adiponectin, respectively. Serum concentrations of IL-6 were measured by a high-sensitivity enzyme-linked immunosorbent assay system (Quantikine HS; R&D System Europe Ltd, United Kingdom). The sensitivity of this assay was ,0.04 pg/mL, with intraassay and interassay CVs ,8% for IL-6. hs-CRP was quantified by using an IMMAGE automatic immunoassay system (Beckman-Coulter, Fullerton, CA). The sensitivity was 0.02 mg/dL. The intraassay and interassay CVs were ,5% and ,7.5%, respectively.
Multiplexed assays of inflammation-related factors
A cytometric bead array (Human Chemokine Kit; BD Biosciences, Franklin Lakes, NJ) was used to assess serum concentrations of monocyte chemoattractant protein 1 (MCP-1), interferon-c-inducible-protein 10 (IP-10), monokine induced by interferon-c (MIG) and RANTES (regulated on activation, normal T cell expressed and secreted) in 10 obese and 14 control subjects. We also used the Human Cytokine 27-Plex Panel kit from Bio-Rad (Hercules, CA) to measure serum concentrations of IL-1, IL-1-receptor antagonist (IL-1-Ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, fibroblast growth factor (FGF), eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon-c, IP-10, platelet-derived growth factor BB, MCP-1, MIP-1a, MIP-1b, tumor necrosis factor-a (TNF-a), RANTES, and vascular endothelial growth factor (VEGF). Multiplex assays were performed according to the manufacturer instructions. Multianalyte profiling was performed on the Luminex-200 system and the Xmap Platform (Luminex Corporation, Austin, TX). Fluorescence data were analyzed with Xponent software by using standard curves obtained from serial dilutions of standard cytokines mixtures. Dilutions of 1:4 were used for serum sample analysis. The chemokine RANTES was readily measurable with the cytometric bead array, but was found to be outside of the standard curve for the 27-Plex assay. In contrast, the same ranges of concentrations were measured for both IP-10 and MCP-1 in both assays (data not shown). IL-8, IL-9, and IL-10 were readily detectable with the 27-Plex kit before surgery, but fell below the detection threshold for at least one point after surgery. This led us to exclude these data in the subsequent statistical analysis, which thereby reduces the sample size for this list of factors, as indicated in the tables.
Statistical analysis
The normal distribution of data was tested by using the Shapiro-Wilk test. Data were log transformed when required. All analyses were adjusted for age. Comparisons between groups were performed by analysis of variance (ANOVA). When the ANOVA procedure showed significant differences, Bonferroni correction was used for post hoc comparisons. Linear modeling allowed for the adjustment of comparisons for confounding variables. Relations between continuous variables were assessed by nonparametric Spearman rank correlation, with adjustment for age and diabetic status. To assess significant differences in postsurgery kinetics analyses, we used repeated-measures multivariate ANOVA for the obese group. Comparisons between preoperative baseline and postsurgery time points were obtained by using paired Student's t test, and P values were Bonferroni corrected. Relations between kinetic changes in inflammatory markers and clinical variables, including food intake (total calories and macronutrients), were tested by building linear mixed-effects models (LMEs) with subjects' identification as a random variable. The inflammationrelated factors IL-8, IL-9, IL-10, and RANTES-having reduced sample sizes because of postoperative values below the detection threshold, were excluded for lack of power. All LME models were fit by maximizing the restricted log-likelihood of their estimated coefficients and were adjusted by age and diabetic status. LME modeling was performed by relying on functions available in the nlme package (17) . Statistical analyses were performed by using R software (version 2.10.1, http://www.r-project.org) or JMP Start Statistics (version 7.0.1; SAS, Cary, NC). A difference was considered significant at P 0.05.
RESULTS
Effect of obesity and type 2 diabetes on circulating inflammation-related factors
The obese and Ob/D women enrolled in the current study had anthropometric and metabolic abnormalities usually associated with severe obesity and type 2 diabetes ( Table 1) . Because the diabetic subjects were older than the obese and lean subjects, all statistical analyses were adjusted for age. We used multiplexed proteomics to investigate systemic inflammatory profiles in these subjects. In a first set of measures, the serum concentrations of 4 chemokines (IP-10, MCP-1, RANTES and MIG) were determined with a cytometric bead assay. These analyses were subsequently augmented with the Luminex 27-Plex assay, which measured 3 cytokines (IL-9, IL-1-Ra, and IL-10), 5 chemokines (IP-10, MIP-1b, MCP-1, IL-8, and eotaxin), and VEGF. Of these, IL-9, IL-1-Ra, IL-10, and IL-8 were below the detection threshold in the control women. After adjustment for age, the concentrations of all factors, except eotaxin, were found to be significantly higher in the obese than in the control women ( Table 1) . Concentrations of individual cytokines and chemokines were found to be highly variable, with MIP-1b having a range of ,1.5-fold and IL-10 a range of .60-fold. IL-10 was found to be higher in the Ob/D group than in the obese and control groups, ie, a 2-fold increase over that in the obese subjects. Conversely, eotaxin was found to be elevated specifically in the Ob/D group compared with the obese group. Differences between the obese and Ob/D groups remained significant when adjusted for BMI (data not shown). These observations indicate that serum levels of a large panel of inflammation-related factors are increased in human obesity, with substantial variability and with additional effects of type 2 diabetes noted for some.
Kinetic evolution of bioclinical characteristics and inflammation-related factors after RYGB in obese subjects
As expected, RYGB resulted in a progressive and steady amelioration of BMI and fat mass and a reduction in fat-free mass, as expected ( Figure 1 and Table 2 ). Postoperative triglyceride and leptin concentrations gradually decreased, whereas adiponectin increased steadily. Circulating glucose and insulin decreased progressively with time, which indicated an amelioration of insulin sensitivity, as further evidenced by increased QUICKI values. Amelioration of glucose homeostasis was confirmed through a steady decrease of glycated hemoglobin. The reduction in total cholesterol was accompanied by an increased HDL-cholesterol concentration at 12 mo. These kinetic profiles were similar between the obese and Ob/D subjects (see Supplementary Figure 1 under "Supplemental data" in the online issue).
An analysis of total energy and macronutrients intakes showed a drastic caloric deduction 3 mo after surgery, with a major effect observed in carbohydrate intake ( Figure 2, A and B) . At 6 mo, energy and carbohydrate consumption rebounded to '70% of initial values and stabilized at 1 y (Table 2) .
A similar biphasic profile of variation was observed for 8 cytokines in the serum. IL-9, IL-10, MIP-1b, MCP-1, IL-8, RANTES, eotaxin, and VEGF all sharply decreased by 3 mo, reaching 220% to 270% of the initial values before returning to near preoperative values at 6 mo ( Figure 2C ). In contrast, IP-10 and IL-1-Ra remained essentially stable over this period, and MIG concentrations steadily increased (Table 2 and Figure 2D ). At 1 y, most of the measured cytokines remained stable or slightly below the baseline values (Table 2) . Strikingly, these profiles did not parallel the decrease in the acute phase response protein hs-CRP and the inflammatory cytokine IL-6 ( Figure 1D ). The variation profiles were similar between the obese and Ob/D subjects for all measured factors (see Supplementary Figure 2 under "Supplemental data" in the online issue).
Because we observed that changes in energy intake had a biphasic profile similar and concomitant to that of many serum factors measured in this study, we sought to test this relation using an LME model adjusted for age and diabetic status, with caloric intake and BMI at 0, 3, and 6 mo set as fixed effects. Significant associations between variations in energy intake and serum concentrations were detected for MIP-1b (P = 0.002), MCP-1 (P = 0.002), and VEGF (P = 0.027), but not for eotaxin (P = 0.113), IL-1-Ra (P = 0.444), or IP-10 (P = 0.250). Similarly, variations in carbohydrate intake were significantly associated with serum concentrations of MIP-1b (P = 0.014), MCP-1 (P , 0.001), VEGF (P = 0.024), and eotaxin (P = 0.045), but not with IL-1-Ra (P = 0.526) or IP-10 (P = 0.128). In contrast, variations in lipid intake were only associated with changes in MIP-1b concentrations (P = 0.021). No significant associations with protein consumption were found. This suggests that a decrease in carbohydrate consumption prominently influences the serum concentrations of a subset of inflammatory factors during the first 3 mo after RYGB.
A long-term assessment of metabolic and serum factors was performed in 19 obese subjects included in the initial population and followed up to 2 y after RYGB. As expected, this group of subjects had an amelioration of corpulence, metabolic status, and systemic inflammation, as evidenced by BMI, QUICKI, and hs-CRP values (Figure 3 ). This was paralleled by a reduction in IL-1-Ra, MCP-1 MIP-1b, VEGF, and eotaxin 2 y after surgery, whereas IP-10 remained unchanged.
DISCUSSION
Little previous information is available about the spectrum of circulating inflammatory factors modified by obesity and the 1 IL, interleukin; IL-1-Ra, IL-1-receptor antagonist; hs-CRP, high-sensitivity C-reactive protein; IP-10, interferonc-inducible protein-10; MIP-1b, macrophage inflammatory protein 1b; MCP-1, monocyte chemoattractant protein 1; RANTES, regulated upon activation, normal T cell expressed and secreted; MIG, monokine induced by interferon-c; VEGF, vascular endothelial growth factor; QUICKI, Quantitative Insulin Sensitivity Check Index; ND, not determined. *Significantly different from nonobese, P , 0.050. § Significantly different from obese, P , 0.050. 2 Obtained by one-factor ANOVA on log-transformed data adjusted for age. When the ANOVA showed a significant difference, Bonferroni correction was used for post hoc comparisons.
3 Mean 6 SEM (all such values). 4 Nonadjusted. 5 Data missing for 2 obese subjects and 1 Ob/D subject. 6 Data available for 14 nonobese, 10 obese, and 10 Ob/D subjects. 7 Below detection threshold indicated. 8 Data available for 14 nonobese and 10 obese subjects.
potential improvement associated with weight reduction. In this study we sought to measure circulating concentrations of a large panel of inflammatory factors in a population of obese women during RYGB-induced weight loss. Contrary to our expectations, only 9 of 27 factors were readily measurable with the 27-Plex kit used. Of these, 3 cytokines (IL-9, IL-10, and IL-1-RA) and 1 chemokine (IL-8) were undetectable in the serum of normalweight women. Except for eotaxin, all of the measured factors were found to be increased in obese individuals, although the amount of increase was strikingly different depending on the factor being measured. These results suggest that distinct sensitivity to regulatory factors or distinct regulatory mechanisms, which remain to be defined, contribute to determining the circulating concentrations of these inflammation-related proteins in obesity. Cytokines and chemokines are low-molecular-weight secreted proteins that can be categorized according to their pro-or antiinflammatory functions (18) . Here, we found up-regulation of these factors in serum, regardless of their known proinflammatory (IL-8, IP-10, MIG, MCP-1, and RANTES) or antiinflammatory (IL-1-Ra and IL-10) role in human physiology. This suggests that obesity is associated with a general inflammatory response and is not restricted to proinflammatory factors. As previously observed in populations of patients undergoing gastric surgery (13) , 35% of the severely obese participants were categorized as having type 2 diabetes. In our study, only IL-10 was higher in the Ob/D women than in the obese women, and eotaxin was the sole factor to be exclusively increased in Ob/D. These data indicate that type 2 diabetes influences a limited number of inflammatory factors, in contrast with the more widespread effect of obesity. Previously, Herder et al (5, 19) reported a specific association of type 2 diabetes with serum concentration of RANTES and IL-8, but not with eotaxin, in a large population of normal and overweight men and women. Currently, we have no clear explanation for the discrepancy observed with eotaxin. It is possible, however, that specific factors related to sex and/or to the severity of the obese phenotypes in the 2 cohorts could have contributed to this difference in observations. Several cytokines and chemokines that were elevated in our cohort of obese subjects have been implicated in the pathogenesis of inflammatory diseases, such as asthma, inflammatory processes in the vascular wall, and an increased risk of coronary artery disease and/or tumor development (20) (21) (22) (23) (24) (25) . Thus, it is tempting to speculate that elevated concentrations of these factors contribute to the high incidence of these diseases in obesity.
RYGB is a well-established procedure used to reduce body fat mass and ameliorate the metabolic status of severely obese subjects. The fat mass and fat-free mass losses observed in our study are consistent with those in previous studies (26, 27) . The effects of surgery-or diet-induced weight-loss on circulating inflammation-related factors were previously reported in separate studies. Gastric surgery is known to reduce serum VEGF (28) and MCP-1 concentrations (29, 30) . Serum eotaxin decreased after diet-induced weight reduction (31), whereas other factors, such as IL-10 (32) or IL-8 (33), were found to be less affected. In one study, changes in the serum concentrations of MCP-1, IL-1-Ra, and IP-10 were related to the amount of weight loss, whereas others, including IL-10 and IL-8, showed no significant correlation (34) . For the first time, our study showed an unexpected pattern of acute variation for a large panel of cytokines and other inflammatory factors at early time points after RYGB. This pattern was characterized by drastic decreases in measured molecules shortly after surgery, followed by a rebound and eventual stabilization at later time points. Three factors-IL-1-Ra, MIG, and IP-10-did not follow this generalized pattern over the course of the study. Thus, not all of the cytokines measured in the same serum sample had similar kinetics, which ruled out an influence of sample treatment. We also ruled out an effect of anesthesia or surgery. Indeed, patients who had complications related to anesthesia and/or surgery (abscess, fistula, or infections) were excluded from the study. Furthermore hs-CRP, an established marker of acute inflammation, was verified and was lower in all patients 3 mo after surgery and at all of the postoperative follow-ups, which ruled out a potential bias related to seasonal-or surgery-related infection.
In the search for bioclinical characteristics associated with early changes in serum cytokines, we observed similar and concomitant drastic variations in energy intake. These parallel profiles were further supported by a multivariate analysis that showed significant associations between kinetic changes in energy intake and selected circulating cytokines. These results indicate that a reduced energy intake is a regulatory factor influencing the systemic inflammatory profile of obese subjects during the first 3 mo after surgery. Furthermore, we highlighted here the influence of macronutrients, with associations between variations in carbohydrate intake and changes in the concentration of a distinct subset of measured cytokines. In clinical practice, it is well known that food intake is substantially modified after RYGB. In the first year, food habits are characterized by a lower consumption of sugars that are sometimes responsible for Dumping Syndrome. Compared with carbohydrate intake, lipid and protein intakes do not appear to have a major influence on serum cytokines concentrations. However, 1 All values are means 6 SEMs. IL, interleukin; IL-1-Ra, IL-1-receptor antagonist; IP-10, interferon-c-inducible protein 10; hs-CRP, high-sensitivity C-reactive protein; MIP-1b, macrophage inflammatory protein 1b; MCP-1, monocyte chemoattractant protein 1; RANTES, regulated upon activation, normal T cell expressed and secreted; MIG, monokine induced by interferon-c; VEGF, vascular endothelial growth factor; QUICKI, Quantitative Insulin Sensitivity Check Index; ND, not determined. *Significantly different from baseline, P , 0.050.
2 Obtained by using repeated-measures multivariate ANOVA. Comparisons between preoperative baseline and each time point after gastric surgery were obtained by paired Student's t test. P values were Bonferroni corrected.
3 Data available for 20 subjects. 4 Data available for 10 obese subjects. 5 Data missing for 3 subjects.
our study on dietary intake was incomplete and requires further research to evaluate the role of different categories of amino acids and/or fatty acids. Indeed, it is suspected that amino acid intake is liable to impair immune function (35) . Finally, modifications of polyunsaturated and unsaturated fats or ratios of x-3 (n23) to x-6 (n26) essential fatty acids were proved to directly participate in systemic and adipose tissue inflammation (36) (37) (38) . The long-term assessment of inflammation-related factors showed steady decreases in virtually all of the cytokines, except IP-10, which remained stable during the entire period of weight loss. BMI reduction and amelioration of metabolic status accompanied the overall reduction in cytokines, which suggests that beneficial effects of reduced corpulence might predominate in regulating long-term circulating cytokine concentrations.
An important outstanding question concerns the cell origin of circulating inflammation-related factors in obesity. It has been established that adipose tissue in obese subjects is infiltrated by immune cells (4) able to produce cytokines. Increased secretion of several cytokines and chemokines, such as MCP-1 (39), IL-10, RANTES, or IL-8 (40) , by human adipose tissue has been reported in obesity. We and others have shown that decreased proinflammatory gene expression in adipose tissue is significantly associated with weight loss (12, 41, 42) . Whether adipose tissue secretion contributes to the acute variations observed in this study with obesity and during weight loss needs to be further clarified. Circulating cytokines are also produced by blood cells. It has been shown that, in obese subjects, peripheral mononuclear cells are characterized by an inflammatory activation (6, 8) that also improves with weight loss (7, 43) . In parallel, the induction of reactive oxygen species and the activation of endoplasmic reticulum stress occur and decrease after surgery-induced weight reduction (44) . It is therefore possible that, in addition to adipocytes, circulating leukocytes and/or endothelial cells participate in the regulation of circulating inflammatory factors with obesity and weight reduction.
In conclusion, this study provides new insights into the overall inflammatory profile in obese subjects and its evolution during weight loss. We highlight coordinated changes in many serum factors, including several cytokines and chemokines, which are elevated in obese subjects and decrease with energy restriction. Our data emphasize that changes in a patient's nutritional status is an important contributor to systemic inflammation during the early phase of rapid and drastic weight loss, whereas reduced corpulence might prevail in regulating circulating cytokine concentrations at later time points. Additional studies are required to identify the molecular and cellular actors involved in the acute down-regulation of systemic cytokines that occurs shortly after RYGB-induced weight loss. Indeed, this study strongly suggests that distinct mechanisms might be involved in the amelioration of systemic inflammatory response at early and late time points during the course of weight reduction in obese subjects.
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